title: Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44.
authors.forename: John D
authors.initials: JD
authors.lastname: Grabenstein
authors.forename: Megan A
authors.initials: MA
authors.lastname: O'Brien
authors.forename: Jieling
authors.initials: J
authors.lastname: Chen
mesh_terms: D006801:Humans; D011008:Pneumococcal Infections / Q000191:economics* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics* / Q000276:immunology*; D011634:Public Health / Q000191:economics*
chemical_list: D022242:Pneumococcal Vaccines